Literature DB >> 16738063

HIFing the brakes: therapeutic opportunities for treatment of human malignancies.

Joseph A Garcia1.   

Abstract

The unfortunate ability of tumor cells to survive and expand in an uncontrolled manner has captivated the attention of clinicians and basic scientists alike. The molecular mechanisms that tumor cells use to grow are the very same pathways used in normal cell growth and differentiation. One important pathway conferring a growth advantage on tumor cells is the epidermal growth factor receptor (EGFR) pathway. Signaling through the EGFR leads to activation of the phosphatidylinositol 3-kinase and Akt pathway and to increased activity of multiple effectors, including hypoxia-inducible factors (HIFs), which are cellular transcription factors involved in environmental stress response. The target genes that HIF members stimulate that are relevant to tumor growth include transcriptional activators and repressors and cytokines and growth factors, as well as their receptors. In this Perspective, findings from several recent studies are discussed in terms of their effect on the signal transducers, target genes, and tumor properties that are ultimately affected during EGFR-stimulated HIF signaling in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16738063     DOI: 10.1126/stke.3372006pe25

Source DB:  PubMed          Journal:  Sci STKE        ISSN: 1525-8882


  18 in total

1.  Akt1 is necessary for the vascular maturation and angiogenesis during cutaneous wound healing.

Authors:  Payaningal R Somanath; Juhua Chen; Tatiana V Byzova
Journal:  Angiogenesis       Date:  2008-04-16       Impact factor: 9.596

2.  IQGAP1, AmotL2, and FKBP51 Scaffoldins in the Glioblastoma Microenvironment.

Authors:  Deborah Rotoli; Manuel Morales; María-Del-C Maeso; Julio Ávila; Natalia D Pérez-Rodríguez; Ali Mobasheri; Cornelis J F van Noorden; Pablo Martín-Vasallo
Journal:  J Histochem Cytochem       Date:  2019-02-22       Impact factor: 2.479

Review 3.  Neuronal-astrocyte metabolic interactions: understanding the transition into abnormal astrocytoma metabolism.

Authors:  Dennis A Turner; David Cory Adamson
Journal:  J Neuropathol Exp Neurol       Date:  2011-03       Impact factor: 3.685

4.  Adaptive prediction model in prospective molecular signature-based clinical studies.

Authors:  Guanghua Xiao; Shuangge Ma; John Minna; Yang Xie
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

5.  Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism.

Authors:  Maria Vittoria Arcidiacono; Mario Cozzolino; Noah Spiegel; Masanori Tokumoto; Jing Yang; Yan Lu; Tetsuhiko Sato; Carlo Lomonte; Carlo Basile; Eduardo Slatopolsky; Adriana S Dusso
Journal:  J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 10.121

6.  Three autocrine feedback loops determine HIF1 alpha expression in chronic hypoxia.

Authors:  Amina A Qutub; Aleksander S Popel
Journal:  Biochim Biophys Acta       Date:  2007-07-20

Review 7.  Multiscale models of angiogenesis.

Authors:  Amina A Qutub; Feilim Mac Gabhann; Emmanouil D Karagiannis; Prakash Vempati; Aleksander S Popel
Journal:  IEEE Eng Med Biol Mag       Date:  2009 Mar-Apr

8.  Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.

Authors:  N Burrows; J Resch; R L Cowen; R von Wasielewski; C Hoang-Vu; C M West; K J Williams; G Brabant
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

9.  Molecular mechanisms of HIF-1alpha modulation induced by oxygen tension and BMP2 in glioblastoma derived cells.

Authors:  Francesca Pistollato; Elena Rampazzo; Sara Abbadi; Alessandro Della Puppa; Renato Scienza; Domenico D'Avella; Luca Denaro; Geertruy Te Kronnie; David M Panchision; Giuseppe Basso
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

10.  Adenomatous polyposis coli and hypoxia-inducible factor-1{alpha} have an antagonistic connection.

Authors:  Ian P Newton; Niall S Kenneth; Paul L Appleton; Inke Näthke; Sonia Rocha
Journal:  Mol Biol Cell       Date:  2010-09-15       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.